OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer
July 13, 2016 06:30 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - July 13, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development...
OncBioMune Research Shows Activity of PGT Technology in a Mammary Cancer Animal Model
July 06, 2016 09:36 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - July 06, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development...
OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches
June 14, 2016 10:02 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - June 14, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development...
Mexican Regulatory Authorities Supportive of OncBioMune's Phase 2 of ProscaVax for Prostate Cancer
June 02, 2016 08:30 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - June 02, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment
May 24, 2016 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - May 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer
May 18, 2016 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - May 18, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
May 11, 2016 09:10 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - May 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
May 04, 2016 08:30 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - May 04, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in China
April 28, 2016 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - April 28, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
OncBioMune Enters Joint Venture, Preparation for Phase 2 Trial of Novel Cancer Vaccine for Prostate Cancer Underway
April 20, 2016 08:00 ET
|
OncBioMune Pharmaceuticals, Inc.
BATON ROUGE, LA--(Marketwired - April 20, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the...